Previous 10 | Next 10 |
SAN CARLOS, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today provided a regulatory update for its tumor-infiltrating lymphocyte (TIL) therapy lifileucel...
SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the BTIG Biotechnology Conference 2020 (Virtual) ...
Iovance Biotherapeutics, Inc. (IOVA) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Sara Pellegrino - Vice President Investor and Public Relations Maria Fardis - President and Chief Executive Officer Friedrich Finckenstein - Chief Medical Officer ...
Iovance Biotherapeutics (NASDAQ: IOVA ) : Q2 GAAP EPS of -$0.47 beats by $0.05 . More news on: Iovance Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN CARLOS, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte, PBL), today reported second quarte...
TUSTIN, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to b...
SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, August 6, 2020. Management will hos...
Cell therapies are increasingly being added to drug pipelines across the biopharmaceutical industry, but Iovance Biotherapeutics (NASDAQ: IOVA) was one of the first movers with its tumor-infiltrating lymphocytes (TILs). In fact, the company is likely to earn marketing approval for two drug c...
It has been widely accepted that tumor cells are antigenic, due to the somatic mutations which alter their protein structure/expression profile and being recognized as “foreign” by the immune system. Further, it has long been known that TILs are common among various cancer types ...
Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-29 05:00:08 ET Joseph Catanzaro from Piper Sandler issued a price target of $10.00 for IOVA on 2024-07-29 02:11:00. The adjusted price target was set to $10.00. At the time of the announcement, IOVA was trading at $9.25. The overall price target consensus is at $...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...